Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344].

[1]  A. Pont,et al.  Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study , 2004, Thorax.

[2]  R. Herings,et al.  N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[3]  E. Wouters.  Economic analysis of the Confronting COPD survey: an overview of results. , 2003, Respiratory medicine.

[4]  J. Suchánková,et al.  Oral N‐acetylcysteine attenuates the rat pulmonary inflammatory response to antigen , 2003, European Respiratory Journal.

[5]  Chi‐Hang Lee,et al.  Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. , 2003, JAMA.

[6]  D. Nowak,et al.  Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. , 2001, Respiratory medicine.

[7]  R. Wood‐Baker,et al.  Oral corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. , 2001, The Cochrane database of systematic reviews.

[8]  W Zidek,et al.  Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. , 2000, The New England journal of medicine.

[9]  L. Davies,et al.  Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial , 1999, The Lancet.

[10]  F. Vanderbist,et al.  Effect of the mucoactive drug nacystelyn on the respiratory burst of human blood polymorphonuclear neutrophils. , 1997, Pulmonary pharmacology & therapeutics.

[11]  K. Aben,et al.  Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[12]  L. Fabbri,et al.  Airway eosinophilia in chronic bronchitis during exacerbations. , 1994, American journal of respiratory and critical care medicine.

[13]  W. MacNee,et al.  Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. , 1994, Thorax.

[14]  W. MacNee,et al.  Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. , 1991, Thorax.

[15]  G. Ricevuti,et al.  Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. , 1988, Thorax.

[16]  J. Brouwers,et al.  Erythromycin and bromhexine in acute exacerbations of chronic bronchitis. A study on sputum penetration and clinical effectiveness. , 1982, European journal of respiratory diseases.

[17]  J. Langlands,et al.  Double-blind clinical trial of bromhexine as a mucolytic drug in chronic bronchitis. , 1970, Lancet.

[18]  J. Nadel,et al.  Role of Neutrophils in Mucus Hypersecretion in COPD and Implications for Therapy , 2004, Treatments in respiratory medicine.

[19]  A. Gazzaniga,et al.  Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. , 1980, European journal of respiratory diseases. Supplement.